Loading…
Employees: 822
Size Seegene (096530.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $915M, the 245th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩31,000 on 6 Nov 2026.
Performance Over six months the shares gained 26.3%, against -16.6% for the median peer and -24.5% for the South Korea market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 12.1% over the last twelve months (peer median +6.3%); the operating margin is 12.9% (peer median 11.2%).
Valuation It trades at 15.9× forward earnings against a peer median of 23.6× (4th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is -16%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.8 points above its cost of capital (6.4% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩509B | ₩474B | ₩414B | ₩367B | ₩854B |
| Revenue growth | — | +14% | +13% | -57% | — |
| Gross profit | ₩300B | ₩271B | ₩205B | ₩180B | ₩466B |
| EBITDA | ₩133B | ₩105B | ₩54.7B | ₩35.7B | ₩239B |
| Net income | ₩80.2B | ₩48.3B | -₩8.76B | ₩669M | ₩182B |
| Free cash flow | ₩99.9B | ₩112B | ₩45.4B | ₩69.8B | ₩256B |
| Capital expenditure | ₩61.6B | ₩40.5B | ₩43.6B | ₩31.9B | ₩72.5B |
| Total debt | ₩130B | ₩130B | ₩144B | ₩142B | ₩159B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 096530.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -20.3% | -3.3% | 2nd lowest of 21 |
| 6-month return | +26.3% | -16.6% | 2nd highest of 21 |
| Distance from 52-week high | -23.4% | -38.7% | 5th highest of 21 |
| Revenue growth (TTM) | +12.1% | +6.3% | 9th highest of 21 |
| Operating margin | 12.9% | 11.2% | 9th highest of 21 |
| Forward P/E | 15.9× | 23.6× | 4th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -3.4% | 7.1% | 4th least demanding of 17 |
| Growth delivered (Del g) | -15.9% | +11.9% | lowest of 17 |
| Hurdle (Req g minus delivered) | +12.5 pp | -5.0 pp | 5th most demanding of 17 |
| ROIC minus cost of capital | +1.8 pp | +3.6 pp | 9th lowest of 21 |
| EV / EBITDA | 5.9× | 10.3× | cheapest of 11 |
| Net debt / EBITDA | -3.4× | -0.3× | 3rd least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Seegene 096530.KS | South Korea | $915M | +26% | +12% | 13% | 15.9× | -3.4% | -15.9% |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $915M | -30% | +36% | 14% | n/a | 47.2% | +17.1% |
| LifeTech Scientific 1302.HK | Hong Kong | $914M | -18% | +1% | 12% | 23.5× | 13.3% | +15.5% |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $919M | -20% | +17% | 18% | 27.1× | 19.9% | +23.3% |
| Beijing SDL Technology 002658.SZ | China | $910M | -21% | -13% | 9% | 23.6× | 18.0% | +2.9% |
| Shanghai Runda Medical Technology 603108.SS | China | $909M | -25% | -12% | -2% | 25.1× | 22.2% | -0.2% |
| Mani 7730.T | Japan | $909M | -15% | +10% | 30% | 18.4× | 1.5% | +13.9% |
| Bioventus BVS | United States | $894M | +1% | +4% | 10% | 13.1× | 6.9% | +12.1% |
| Caina Technology 301122.SZ | China | $938M | +60% | +61% | 0% | 72.0× | n/a | n/a |
| Safilo SFL.MI | Italy | $890M | +24% | -4% | 9% | 16.0× | -0.5% | +4.7% |
| Cisen Pharmaceutical 603367.SS | China | $890M | -15% | -6% | 8% | 8.3× | -12.9% | -1.3% |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $944M | -19% | +4% | 30% | n/a | 13.1% | +4.6% |
| Shenzhen YHLO Biotech 688575.SS | China | $950M | -20% | +3% | 12% | 37.2× | 3.1% | +12.7% |
| Kuros Biosciences KURN.SW | Switzerland | $953M | +3% | +41% | 6% | 73.8× | n/a | n/a |
| Modern Dental 3600.HK | Hong Kong | $871M | +19% | +12% | 22% | 8.8× | -7.0% | +11.3% |
| Sino Medical Sciences Technology 688108.SS | China | $868M | -35% | +22% | 19% | 69.2× | 31.0% | +9.9% |
| Beijing Hotgen Biotech 688068.SS | China | $966M | -38% | +8% | -94% | n/a | n/a | n/a |
| JINS 3046.T | Japan | $865M | -12% | +14% | 10% | 16.6× | -7.2% | +11.7% |
| Eckert & Ziegler EUZ.DE | Germany | $969M | -7% | +4% | 25% | 17.0× | 7.2% | +12.1% |
| MedCap MCAP.ST | Sweden | $864M | +6% | +17% | 15% | 26.4× | 2.9% | +20.9% |
| Xiangyu Medical 688626.SS | China | $969M | -31% | 0% | 4% | 62.1× | n/a | n/a |